Efficacy and Safety of VDPHL01 in Males with AGA

Inclusion Criteria:

• Subject is male aged 18-65 years old;

• Subject has a clinical diagnosis of mild to moderate AGA;

• Subject is in good general health and has normal renal and hepatic function;

• Subject is willing to maintain at least 1/4 inch length hair during the study withthe same hairstyle, hair length, and hair color throughout the study; maintainconsistent use of general hair care products and regimen through the entire study;

• Subject is willing and able to administer the test article as directed read,understand, and complete required questionnaires in English;

• Subject is willing and able to swallow study drug whole;

• Subject agrees to have a micro dot tattoo placed on their scalp;

• Subject agrees to have this area photographed at study visits as indicated in theprotocol.

Exclusion Criteria:

• Subject has uncontrolled blood pressure;

• Subject has symptoms or history of certain heart or thyroid conditions;

• Subject has a history of cardiac and/or thyroid diseases;

• Subject has received an organ transplant;

• Subject has a history of prescription drug abuse or illicit drug use within 6 monthsof screening; history of alcohol abuse within 6 months prior to screening;

• Subject has a current or recent history of dietary or weight changes;

• Subject has been diagnosed with COVID-19 within 16 weeks of baseline;

• Subject has used any topical scalp treatments for hair growth within 4 weeks priorto screening;

• Subject has had any scalp procedures, including surgical, laser, light or energytreatments, micro-needling, etc. within 6 months prior to screening

• Subject has had previous radiation of the scalp

• Subject has used systemic cimetidine, ketoconazole, diazoxide, or corticosteroids (including intramuscular, intraarticular, and intralesional injections) within 12weeks prior to screening

• Subject has used systemic beta blockers within 12 weeks prior to screening

• Subject is currently enrolled in an investigational drug, biologic, or device studyor has used an investigational treatment within 30 days prior to screening

• Subject has used any other therapy with any medication either topical or oral thatmight, in the investigator's opinion, interfere with the study